Benign prostatic hyperplasia/urinary retention:
Indications for: RAPAFLO
Benign prostatic hyperplasia.
Adult Dosage:
Take with food once daily. Normal renal function: 8mg. Renal impairment (CrCl 30–50mL/min): 4mg. Difficulty swallowing pills/caps: may open caps and sprinkle contents on a tablespoonful of applesauce; swallow immediately (within 5mins) without chewing and follow with an 8oz glass of water.
Children Dosage:
Not established.
RAPAFLO Contraindications:
Severe renal impairment (CrCl <30mL/min). Severe hepatic impairment (Child-Pugh score ≥10). Concomitant potent CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin, ritonavir).
RAPAFLO Warnings/Precautions:
Not for treating hypertension. Exclude prostate cancer. Anticipated cataract surgery (may cause intraoperative floppy iris syndrome; advise ophthalmologist). Pregnancy, nursing mothers: not indicated for use in females.
RAPAFLO Classification:
Alpha-1 blocker.
RAPAFLO Interactions:
See Contraindications. Concomitant other α-blockers, other strong P-glycoprotein inhibitors (eg, cyclosporine): not recommended. May be potentiated by moderate CYP3A4 inhibitors (eg, erythromycin, diltiazem, verapamil). Caution with other antihypertensives or PDE-5 inhibitors.
Adverse Reactions:
Retrograde ejaculation, dizziness, diarrhea, orthostatic hypotension, headache, nasopharyngitis, nasal congestion.
Drug Elimination:
Fecal, renal.
Generic Drug Availability:
YES
How Supplied:
Caps—30, 90
